ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with CirrhosisFred Poordad, Barry Bernstein, Christophe Hézode et al.|New England Journal of Medicine|2014Cited by 877
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionMarc Bourlière, Stefan Zeuzem, Stuart C. Gordon et al.|New England Journal of Medicine|2017Cited by 565
Impact of COVID-19 on global HCV elimination effortsSarah Blach, Antonio Craxı̀, Loreta A. Kondili et al.|Journal of Hepatology|2020Cited by 279
Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given lateAdriano Pellicelli, M. Angélico, Marzia Montalbano et al.|Digestive and Liver Disease|2014Cited by 103
Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territoriesDevin Razavi‐Shearer, Nicola Coppola, Hannah Child et al.|Journal of Hepatology|2023Cited by 94